Blood Screening Market size is valued at USD 2,225 million in 2021 and is expected to grow at a CAGR of 8.6% during the forecast period 2022 to 2028. Blood screening is defined as various tests done on blood samples for the diagnosis of numerous diseases such as AIDS, syphilis, hepatitis treatment, and other clinical circumstances such as pregnancy. It aids in monitoring diseases and avoiding health issues and a variety of other conditions such as cancer and infections. Blood donor screening is the protection mechanism employed against the spread of infection before blood donation. The global market provides a detailed overview of the Blood Screening market, and that can be segmented by product, by technology, and by end user. By product, the Blood Screening market has been segmented into Instrument, Reagents & Kits, and Software. The reagents & kits segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to an increase in blood transfusion events, because of which there is more repeated use and consumption of reagents & kits in blood screening process. Based on Technology, the Nucleic Acid Amplification, Elisa, Rapid test, NGS, and Western Blotting. Among these, the Nucleic Acid Amplification segment is expected to have the fastest-growing market during the forecast period 2022-2028. The major factor for rising of this segment is the growing acceptance of nucleic acid amplification technology due to its increased sensitivity over other blood screening techniques. Apart from this, the increasing number of blood donations can also drive the growth of this segment. Based on the End user, the Blood Screening market is segmented into Blood banks and Hospitals. The Blood banks segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the increasing number of organ transplants.
In September 2021, Roche Diagnostics acquired TIB Molbiol Group to expand its business in molecular diagnostics.
In February 2020, BD (US) acquired NAT Diagnostics (US), to enhance a molecular diagnostic platform for POC testing.